Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

November 25, 2020November 25, 2020

Ultomiris as Shorter Infusion Approved in Europe to Treat aHUS

News

The European Commission has approved a new intravenous formulation of Ultomiris (ravulizumab) to treat for adults and children with atypical hemolytic uremic syndrome (aHUS) that allows the medication to be ... Read more

October 14, 2020October 14, 2020

FDA Approves New Ultomiris Formulation That Shortens Infusion Time

News

The U.S. Food and Drug Administration (FDA) has approved a new formulation of Ultomiris (ravulizumab), a treatment for adults and children with atypical hemolytic uremic syndrome (aHUS), that allows the ... Read more

September 30, 2020September 30, 2020

Japan Approves Ultomiris to Treat Patients With aHUS

News

Ultomiris (ravulizumab) has been approved in Japan for the treatment of adults and children with atypical hemolytic uremic syndrome (aHUS). Developed and marketed by Alexion Pharmaceuticals, Ultomiris is the ... Read more

September 9, 2020September 9, 2020

60K More aHUS Patients Would Be Alive Worldwide if Given Appropriate Healthcare, Alliance Says

News

The aHUS Alliance Global Action estimates there could be 84,000 people living with atypical hemolytic uremic syndrome (aHUS) in the world today — roughly 60,000 more than current estimates ... Read more

July 29, 2020July 29, 2020

Mutations Affecting C3 Protein Activity Linked to aHUS in Case Report

News

Mutations leading to the overactivation of the complement regulator protein C3 should be recognized as a cause of atypical hemolytic uremic syndrome (aHUS), a case report highlights. The report, ... Read more

May 27, 2020May 27, 2020

Ultomiris Safe, Effective at Resolving Life-threatening Complications of aHUS, Trial Results Show

News

Ultomiris (ravulizumab-cwvz) is safe and effective at resolving acute and life-threatening complications of atypical hemolytic uremic syndrome (aHUS) in adults with thrombotic microangiopathy (TMA), Phase 3 clinical trial data ... Read more

March 25, 2020March 25, 2020

Tekturna Seen to Treat High Blood Pressure Associated with aHUS

News

A medication for high blood pressure, Tekturna (aliskiren) may be used as an add-on therapy to manage hypertension associated with atypical hemolytic uremic syndrome (aHUS) until more adequate treatments become available, ... Read more

February 10, 2020February 10, 2020

Understanding aHUS-linked Changes in Large Gene Cluster May Help in Diagnosis and Treatment, Review Says

News

Understanding the disease-related alterations in a large gene cluster that lead to atypical hemolytic uremic syndrome (aHUS) may help in diagnosing and treating the illness, a recent review suggests. ... Read more

January 27, 2020January 27, 2020

Experts Propose New Diagnostic Criteria to Distinguish TMA Associated With aHUS

News

Experts in South Korea have proposed a set of new diagnostic criteria to distinguish thrombotic microangiopathy associated with atypical hemolytic uremic syndrome (aHUS). Their study, “Consensus regarding diagnosis and ... Read more

October 23, 2019October 23, 2019

FDA Approves Alexion’s Ultomiris for Treating aHUS in Children and Adults

News

The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) for the treatment of adults and children ages one month and older with atypical hemolytic uremic syndrome (aHUS), ... Read more